Streetbeat News

Analyst Ratings

JANX

Wedbush analyst David Driscoll maintains an Outperform rating on Janux Therapeutics (NASDAQ:JANX) and raises the price target from $24 to $53.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:56 pm

HSII

Truist Securities analyst Tobey Sommer has maintained a Hold rating on Heidrick & Struggles Intl (NASDAQ:HSII) and increased the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:55 pm

FRPT

Truist Securities analyst Bill Chappell has maintained a Hold rating on Freshpet (NASDAQ:FRPT) and increased the price target from $70 to $120.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:54 pm

RVMD

Wedbush analyst David Driscoll has maintained an Outperform rating on Revolution Medicines (NASDAQ:RVMD) and increased the price target from $41 to $42.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:53 pm

FIS

Truist Securities analyst Andrew Jeffrey has maintained a Hold rating on Fidelity National Information Services (FIS) and increased the price target from $55 to $65.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:52 pm

PLAY

Truist Securities analyst Jake Bartlett has maintained a Buy rating on Dave & Buster's Entertainment (NASDAQ:PLAY) and increased the price target from $66 to $75.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:50 pm

FATE

Wedbush analyst David Nierengarten has maintained a Neutral rating on Fate Therapeutics (NASDAQ:FATE) and increased the price target from $3 to $7.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:49 pm

BNL

Truist Securities analyst Ki Bin Kim has maintained a Hold rating on Broadstone Net Lease (BNL) and reduced the price target from $18 to $17.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:49 pm

ADC

Truist Securities analyst Ki Bin Kim has maintained a Buy rating on Agree Realty (NYSE:ADC) but has lowered the price target from $70 to $68.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:47 pm

CAVA

Wedbush analyst Nick Setyan maintains an Outperform rating on Cava Group (NYSE:CAVA) and sets a price target of $59.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:45 pm